SH Domains

Preliminary Table of Contents1. SH3 domains as suitable models to study amyloid aggregationDr. Francisco ConejeroLara,conejero@ugr.esDr. Bertrand Morel, bmorel@ugr.esDavid Ruzafa druzafa@gmail.comDepartamento de Quimica Fisica e Instituto de Biotecnologia, Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.2. Structure and mechanism of SH2 and SH3 domains Dr. Liwen Jiang ljiang@cuhk.edu.hk School of Life Sciences; Center for Cell and Developmental Biology and State Key Laboratory of Agrobiotechnology; Chinese University of Hong Kong; Hong Kong, China; Shenzhen Research Institute; Chinese University of Hong Kong; Shenzhen, China.3. Versatility of SH3 domains in the celullar machinery Dr. Ana I. Azuaga aiazuaga@ugr.es Departamento de Quimica Fisica e Instituto de Biotecnologia, Facultad de Ciencias, Universidad de Granada, Granada, Spain 4. Structurefunction relationship of bacterial SH3 domains Dr. Shigehiro KAMITORI kamitori@med.kagawa-u.ac.jp Life Science Research Center & Faculty of Medicine, Kagawa University, Japan 5. tba Dr. Cheng chengs@mail.nih.gov Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 208924264, USA6. SH domain's interaction with SliMs (Short Linear Motifs recognized by SH2 and SH3) Dr. Ren Siyuan rsysjtu@hotmail.com Center for Information Science and Technology, Temple University, Philadelphia, PA 19122, USA7. SHP2, the nonreceptor protein tyrosine phosphatase 11 (the role of its SH2 domains in protein function, and the structural and functional impact of mutations in those domains on protein functional dysregulation) Dr. Marco Tartaglia marco.tartaglia@iss.it Marco Tartaglia, PhD, Section Director, Dept. Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena, 299, 00161 Rome, Italy8. SH2 domain structures and interactions Dr. Michael Overduin m.overduin@bham.ac.uk School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, UK9. SH Domains and Epidermal Growth Factor Receptor Dr. Udayan Guha udayan.guha@nih.gov Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA (Putative Dr. Ladbury JELadbury@mdanderson.org Department of Biochemistry and Molecular Biology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA. [2] Center for Biomolecular Structure and Function, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)